On November 3, 2022 Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, reported that six abstracts have been accepted for presentation, including two oral presentations, at the 64th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting to be held December 10-13, 2022 in New Orleans, LA (Press release, Sana Biotechnology, NOV 3, 2022, View Source [SID1234622930]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The presentations at ASH (Free ASH Whitepaper) will showcase the potential for both our allogeneic CAR T cell and in vivo delivery platforms to develop differentiated drugs for patients with hematologic malignancies," said Terry Fry, Sana’s Senior Vice President and Head of T Cell Therapeutics. "We are initially developing therapeutics for patients with lymphoma, leukemia, and multiple myeloma, and we look forward to presenting data on CD19-, CD22- and BCMA-targeted therapeutic candidates at the meeting."

Full abstracts are available for online viewing via the ASH (Free ASH Whitepaper) Annual Meeting website at www.hematology.org/meetings/annual-meeting. In addition, abstracts will be published online in the November supplemental issue of Blood, the journal of the American Society of Hematology (ASH) (Free ASH Whitepaper).